Search PubMed⌕ Search

Biomedical subjects

F Cavalli

Publications and source records attributed to F Cavalli.

At least 271 records · Page 15Linked to original sources
PubMed1981

Cis-dichlorodiammineplatinum (II) and VP 16-213 combination chemotherapy for non-small cell lung cancer.

Twenty-three patients with non-small cell lung cancer were treated with a combination of cis-dichlorodiammineplatinum (II) 100 mg/m2 IV on day 1 and VP 16-213 80 mg/m2 IV on days 1-3. Eighteen patients are evaluable for response. Seven partial remissions with a median duration of 3 months (range, 1-13+) have been observed. Three patients exhibit stable disease, and eight patients show tumor progression. Overall survival was 5+ months (range, 1-13+); 7.5 months (range, 3-13+) for responders and 3+ months (range, 1-9+) for non-responders. Hematologic toxicity was acceptable, but poor subjective tolerance (nausea, vomiting, loss of appetite) was the main factor limiting treatment duration.

Adenocarcinoma↗
PubMed1981

[Randomized phase II study with VP-16-213 (etoposide) in the treatment of advanced breast cancer].

Thirty patients with an advanced and previously heavily pretreated breast cancer were treated in a randomized phase II trial with the new podophyllotoxinderivative VP-16-213. The therapeutic result can be assessed in 28 cases. Half of these patients received the cytotoxic drug orally 150 mg/m2/day during 5 days once every 3 weeks. The other half were randomized to receive the drug i.v. 150 mg/m2 weekly. No clear-cut partial remission was detected among the treated patients. In 3 cases a tumor regression was observed, which only met the criteria for a minor regression. These data are consistent with the single agent activity reported in the literature, which encompass mostly heterogeneous series with a few patients. The antitumoractivity of VP-16-213 in the treatment of breast cancer seems to be moderate. However, this should not prevent its incorporation into future, suitable combination chemotherapies.

Administration, Oral↗
PubMed1981

[Prognostic factors in metastasizing melanoma].

This paper evaluates the prognostic significance of various clinical parameters applied to 133 patients with advanced malignant melanoma, who were treated in two successive studies by the Swiss Group for Clinical Cancer Research (SAKK). All patients received poly chemotherapy. In the second study half of the cases were also randomly allocated to an additional unspecific immunotherapy with MER. The results of the combined chemo-immunotherapy are inferior to those achieved with chemotherapy alone. Patients achieving a partial remission live significantly longer than patients with a progressive disease. Further factors of significant prognostic importance are: the performance status, the sites of metastases, the localization of the primary tumor, and the sex. Based on the data, we propose new parameters for the stratification of patients in future Phase II and Phase III trials.

Adult↗
PubMed1980

[Phase-II-study with cis-diamminedichloroplatinum (II) in the treatment of advanced malignant lymphomas].

29 patients with advanced malignant lymphoma were included in a phase-II trial conducted by Cancer and Acute Leukemia Group B. The patients received cis-diamminedichloroplatinum (DDP) in a dose of 70 mg/m2 every three weeks. In this still ongoing study, 23 patients are already evaluable. Out of 23 cases partial remission was observed in 6. The main toxicity was profuse vomiting. Myelosuppression and nephrotoxicity were both manageable. Based on these preliminary data, the incorporation of DDP in combination chemotherapy for malignant lymphoma appears to be warranted.

Cisplatin↗
PubMed1980

[Phase-II-study with vindesine (desacetyl-vinblastine-amide-sulfate) in advanced malignant diseases].

53 patients with advanced and measurable cancerr were treated with vindesine in doses of 3 mg/m2 (pretreated) and 4 mg/m2 (non pretreated) i.v. once weekly. 48 patients are evaluable for response: of 14 patients with squamous cell carcinoma of the lung, 1 partial remission (PR), 1 minor response (MR) and 1 no change (NC) were observed. In 5 patients with large cell carcinoma of the lung: 1 NC. In 3 with adenocarcinoma of the lung: 1 MR. One patient with nasopharyngeal carcinoma had progressive disease. Stable disease was observed in a patient with carcinoma of the tongue and in a patient with adenocarcinoma of the esophagus. Four patients with colorectal carcinoma had progressive disease. One MR was observed in a patient with breast cancer, while all of the other 3 patients had progressive disease. One carcinoma of the penis was stable. One MR was observed in a patient with Hodgkin's disease. One PR was observed in a case with no-Hodgkin's lymphoma. A patient with acute leukemia had progressive disease. Among 9 patients with malignant melanoma, 3 had an MR and 1 patient had stable disease. A patient with fibrosarcoma had progressive disease. Observed toxicity included leukopenia, thrombocytopenia, anemia, paresthesias, constipation, jaw pain, nausea, stomatitis, alopecia, loss of taste, pruritus and skin rash, weakness and fatigue.

Adenocarcinoma↗
PubMed1980

[Results of a pilot study with high-dose medroxyprogesterone acetate in the treatment of metastasizing breast carcinoma].

Nineteen patients with advanced breast cancer were treated with 1 g medroxyprogesterone acetate (MPA) i.m. daily for 4 weeks. The therapy was well tolerated. The measurable tumor lesions showed a regression of more than 50% in 6 cases; the mean duration of remission was 12 months. In 12 patients the treatment led to a marked subjective improvement. On the basis of these data the authors feel that high-dosage MPA warrants further investigation in the treatment of metastatic breast cancer.

Aged↗
PubMed1980

Simultaneous hormone- and chemotherapy, compared with hormone therapy followed by chemotherapy in the treatment of metastasising mammary carcinoma--preliminary results of a current study.

The preliminary results of an on-going SAKK study on metastasising mammary cancinoma are reported. At the time of writing 210 cases are already evaluable. This study seeks to investigate the question of the necessary intensity of polychemotherapy and also the problem of whether cytostatic therapy should be begun at the same time as hormonal therapy or just after failure of this measure. At present no definite answer is available. The results point to a new, possibly important aspect of the treatment of metastasising mammary carcinoma.

Antineoplastic Agents↗